CardioVascular and Interventional Radiology

, Volume 32, Issue 4, pp 687–694 | Cite as

Transarterial Infusion Chemotherapy Using Cisplatin-Lipiodol Suspension With or Without Embolization for Unresectable Hepatocellular Carcinoma

  • Tomokazu Kawaoka
  • Hiroshi AikataEmail author
  • Shintaro Takaki
  • Yoshio Katamura
  • Akira Hiramatsu
  • Koji Waki
  • Shoichi Takahashi
  • Masashi Hieda
  • Naoyuki Toyota
  • Katsuhide Ito
  • Kazuaki Chayama
Clinical Investigation


We evaluate the long-term prognosis and prognostic factors in patients treated with transarterial infusion chemotherapy using cisplatin-lipiodol (CDDP/LPD) suspension with or without embolization for unresectable hepatocellular carcinoma (HCC). Study subjects were 107 patients with HCC treated with repeated transarterial infusion chemotherapy alone using CDDP/LPD (adjusted as CDDP 10mg/LPD 1ml). The median number of transarterial infusion procedures was two (range, one to nine), the mean dose of CDDP per transarterial infusion chemotherapy session was 30 mg (range, 5.0–67.5 mg), and the median total dose of transarterial infusion chemotherapy per patient was 60 mg (range, 10–390 mg). Survival rates were 86% at 1 year, 40% at 3 years, 20% at 5 years, and 16% at 7 years. For patients with >90% LPD accumulation after the first transarterial infusion chemotherapy, rates were 98% at 1 year, 60% at 3 years, and 22% at 5 years. Multivariate analysis identified >90% LPD accumulation after the first transarterial infusion chemotherapy (p = 0.001), absence of portal vein tumor thrombosis (PVTT; p < 0.001), and Child-Pugh class A (p = 0.012) as independent determinants of survival. Anaphylactic shock was observed in two patients, at the fifth transarterial infusion chemotherapy session in one and the ninth in the other. In conclusion, transarterial infusion chemotherapy with CDDP/LPD appears to be a useful treatment option for patients with unresectable HCC without PVTT and in Child-Pugh class A. LPD accumulation after the first transarterial infusion chemotherapy is an important prognostic factor. Careful consideration should be given to the possibility of anaphylactic shock upon repeat infusion with CDDP/LPD.


Hepatocellular carcinoma Transcatheter arterial chemoembolization Cisplatin-lipiodol suspension Arterial infusion chemotherapy Prognosis 


  1. 1.
    Taylor-Robinson SD, Foster GR, Arora S et al (1997) Increase in primary liver cancer in the UK, 1979–94. Lancet 350:1142–1143PubMedCrossRefGoogle Scholar
  2. 2.
    El-Serag HB, Mason AC (1999) Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 340:745–750PubMedCrossRefGoogle Scholar
  3. 3.
    El-Serag HB (2002) Hepatocellular carcinoma: an epidemiologic view. J Clin Gastroenterol 35:s72–s78PubMedCrossRefGoogle Scholar
  4. 4.
    Okita K (2006) Management of hepatocellular carcinoma in Japan. J Gastroenterol 41(2):100–106PubMedCrossRefGoogle Scholar
  5. 5.
    Livraghi T, Festi D, Monti F et al (1986) US guided percutaneous alcohol injection of small hepatic and abdominal tumours. Radiology 161:309–312PubMedGoogle Scholar
  6. 6.
    Seki T, Wakabayashi M, Nakagawa T et al (1994) Ultrasonically guided percutaneous microwave coagulation therapy for small hepatocellular carcinoma. Cancer 74:817–825PubMedCrossRefGoogle Scholar
  7. 7.
    Amin Z, Donald JJ, Masters A et al (1993) Hepatic metastases: interstitial laser photocoagulation with real-time US monitoring and dynamic CT evaluation of treatment. Radiology 187:339–347PubMedGoogle Scholar
  8. 8.
    Rossi S, Buscarini E, Garbagnati F et al (1998) Percutaneous treatment of small hepatic tumors by an expandable RF needle electrode. AJR 170:1015–1022PubMedGoogle Scholar
  9. 9.
    Buscarini L, Buscarini E, Di Stasi M et al (2001) Percutaneous radiofrequency ablation of small hepatocellular carcinoma: long-term results. Eur Radiol 11:914–921PubMedCrossRefGoogle Scholar
  10. 10.
    Goldstein HM, Wallace S, Anderson JH et al (1976) Transcatheter occlusion of abdominal tumors. Radiology 120:539–545PubMedGoogle Scholar
  11. 11.
    Chuang VP, Wallace S (1981) Hepatic artery embolization in the treatment of hepatic neoplasms. Radiology 140:51–58PubMedGoogle Scholar
  12. 12.
    Yamada R, Sato M, Kawabata M et al (1983) Hepatic artery embolization in 120 patients with unresectable hepatoma. Radiology 148:397–401PubMedGoogle Scholar
  13. 13.
    Ohishi H, Uchida H, Yoshimura H et al (1985) Hepatocellular carcinoma detected by iodized oil. Radiology 154:25–29PubMedGoogle Scholar
  14. 14.
    Takayasu K, Shima Y, Muramatsu Y et al (1987) Hepatocellular carcinoma: treatment with intraarterial iodized oil with and without chemotherapeutic agents. Radiology 162:345–351Google Scholar
  15. 15.
    Nakamura H, Hashimoto T, Oi H et al (1989) Transcatheter oily chemoembolization of hepatocellular carcinoma. Radiology 170:783–786PubMedGoogle Scholar
  16. 16.
    Solomon B, Soulen MC, Baum RA et al (1999) Chemoembolization of hepatocellular carcinoma with cisplatin, doxorubicin, mitomycin-C, Ethiodol, and polyvinyl alcohol: prospective evaluation of response and survival in a U.S. population. J Vasc Interv Radiol 10:793–798PubMedCrossRefGoogle Scholar
  17. 17.
    Nishizaki T, Takenaka K, Yoshida K et al (1995) Influence of lipiodolization on a cirrhotic liver. J Surg Oncol 58:263–268PubMedCrossRefGoogle Scholar
  18. 18.
    Sasaki Y, Imaoka S, Kasugai H et al (1987) A new approach to chemoembolization therapy for hepatoma using ethiodized oil, cisplatin, and gelatin sponge. Cancer 60:1194–1203PubMedCrossRefGoogle Scholar
  19. 19.
    Kasugai H, Kojima J, Tatsuta M et al (1989) Treatment of hepatocellular carcinoma by transcatheter arterial embolization combined with intraarterial infusion of a mixture of cisplatin and ethiodized oil. Gastroenterology 97:965–971PubMedGoogle Scholar
  20. 20.
    Shibata J, Fujiyama S, Sato T et al (1989) Hepatic arterial injection chemotherapy with cisplatin suspended in an oily lymphographic agent for hepatocellular carcinoma. Cancer 64:1586–1594PubMedCrossRefGoogle Scholar
  21. 21.
    Beppu T, Ohara C, Yamaguchi Y et al (1991) A new approach to chemoembolization for unresectable hepatocellular carcinoma using aclarubicin microspheres in combination with cisplatin suspended in iodized oil. Cancer 68:2555–2560PubMedCrossRefGoogle Scholar
  22. 22.
    Nakanishi T, Kitamoto M, Asahara T et al (1991) Effects of hepatic arterial injection chemotherapy with CDDP-LPD for hepatocellular carcinoma. Diagn Imaging Abdomen 11:234–240 (in Japanese)Google Scholar
  23. 23.
    Ngan H, Lai CL, Fan ST et al (1996) Transcatheter arterial chemoembolization in inoperable hepatocellular carcinoma: four-year follow-up. J Vasc Interv Radiol 7:419–425PubMedCrossRefGoogle Scholar
  24. 24.
    Ueno K, Miyazono N, Inoue H et al (2000) Transcatheter arterial chemoembolization therapy using iodized oil for patients with unresectable hepatocellular carcinoma: evaluation of three kinds of regimens and analysis of prognostic factors. Cancer 88:1574–1581PubMedCrossRefGoogle Scholar
  25. 25.
    Konno T, Maeda H, Iwai K et al (1983) Effect of arterial administration of high molecular weight anticancer agent SMANCS with lipid lymphographic agent on hepatoma: a preliminary report. Eur J Cancer Clin Oncol 19:1053–1065PubMedCrossRefGoogle Scholar
  26. 26.
    Ikeda K, Kumada H, Saitoh S et al (1991) Effect of repeated transcatheter arterial embolization on the survival time in patients with hepatocellular carcinoma. An analysis by the Cox proportional hazard model. Cancer 68:2150–2154PubMedCrossRefGoogle Scholar
  27. 27.
    Nakakuma K, Tashiro S, Hiraoka T et al (1983) Studies on anticancer with an oily anticancer drug injected into the ligated feeding hepatic artery for liver cancer. Cancer 52:2193–2220PubMedCrossRefGoogle Scholar
  28. 28.
    Llovet JM, Real MI, Montana X et al (2002) Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomized controlled trial. Lancet 359:1734–1739PubMedCrossRefGoogle Scholar
  29. 29.
    Lo CM, Ngan H, Tso WK et al (2002) Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 35:1164–1171PubMedCrossRefGoogle Scholar
  30. 30.
    Araki T, Hihara T, Kachi K et al (1989) Newly developed transarterial chemoembolization material: CDDP-lipiodol suspension. Gastrointest Radiol 14:46–48PubMedCrossRefGoogle Scholar
  31. 31.
    Ngan H, Lai CL, Fan ST et al (1993) Treatment of inoperable hepatocellular carcinoma by transcatheter arterial chemoembolization using an emulsion of cisplatin in iodized oil and gelfoam. Clin Radiol 47:315–320PubMedCrossRefGoogle Scholar
  32. 32.
    Yamamoto K, Shimizu T, Narabayashi I (2000) Intraarterial infusion chemotherapy with lipiodol-CDDP suspension for hepatocellular carcinoma. CardioVasc Interv Radiol 23:26–39CrossRefGoogle Scholar
  33. 33.
    Yuen MF, Chan AO, Wong BC et al (2003) Transarterial chemoembolization for inoperable, early stage hepatocellular carcinoma in patients with Child-Pugh grade A and B: results of a comparative study in 96 Chinese patients. Am J Gastroenterol 98:1181–1185PubMedGoogle Scholar
  34. 34.
    Liver Cancer Study Group of Japan (2000) The general rules for the clinical and pathological study of primary liver cancer, 4th edn. Tokyo, Kanehara, p 19 (in Japanese)Google Scholar
  35. 35.
    Kamada K, Nakanishi T, Kitamoto M et al (2001) Long-term prognosis of patients undergoing transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma: comparison of cisplatin lipiodol suspension and doxorubicin hydrochloride emulsion. J Vasc Interv Radiol 12:847–854PubMedCrossRefGoogle Scholar
  36. 36.
    Cardella JF, Miller DL, Cole PE, Lewis CA (2003) Society of Interventional Radiology position statement on radiation safety. J Vasc Interv Radiol 14(9; Pt 2):S387PubMedGoogle Scholar
  37. 37.
    NCI Common Toxicity Criteria. Available at
  38. 38.
    Furukawa S (2004) In vitro chemosensitivity of hepatocellular carcinoma for hepatic arterial infusion chemotherapy using the MTT assay with the combinations of antitumor drugs. Kurume Med J 51:25–33PubMedGoogle Scholar
  39. 39.
    Ono Y, Yoshimasu T, Ashikaga R et al (2000) Long-term results of lipiodol-transcatheter arterial embolization with cisplatin or doxorubicin for unresectable hepatocellular carcinoma. Am J Clin Oncol 23:564–568PubMedCrossRefGoogle Scholar
  40. 40.
    Farinati F, De Maria N, Marafin C et al (1996) Unresectable hepatocellular carcinoma in cirrhosis: survival, prognostic factors, and unexpected side effects after transcatheter arterial chemoembolization. Dig Dis Sci 41:2332–2339PubMedCrossRefGoogle Scholar
  41. 41.
    Saccheri S, Lovaria A, Sangiovanni A et al (2002) Segmental transcatheter arterial chemoembolization treatment in patients with cirrhosis and inoperable hepatocellular carcinomas. J Vasc Interv Radiol 13:995–999PubMedCrossRefGoogle Scholar
  42. 42.
    Ikeda M, Maeda S, Shibata J et al (2004) Transcatheter arterial chemotherapy with and without embolization in patients with hepatocellular carcinoma. Oncology 66(1):24–31PubMedCrossRefGoogle Scholar
  43. 43.
    Takaki Y, Kaminou T, Shabana M, Ihaya T, Otsubo K, Ogawa T (2008) Suitable blending method of lipiodol-cisplatin in transcatheter arterial embolization for hepatocellular carcinoma: evaluation of sustained release and accumulation nature. Hepatogastroenterology 55(81):202–206PubMedGoogle Scholar
  44. 44.
    Matsui O, Takahashi S, Kadoya M et al (1994) Pseudolesion in segment IV of the liver at CT during arterial portography: correlation with aberrant gastric venous drainage. Radiology 193:31–35PubMedGoogle Scholar
  45. 45.
    Basu R, Rajkumar A, Datta NR (2002) Anaphylaxis to cisplatin following nine previous uncomplicated cycles. Int J Clin Oncol 7:365–367PubMedCrossRefGoogle Scholar
  46. 46.
    Shlebak AA, Clark PI, Green JA (1995) Hypersensitivity and cross-reactivity to cisplatin and analogues. Cancer Chemother Pharmacol 35:349–351PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC and the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) 2009

Authors and Affiliations

  • Tomokazu Kawaoka
    • 1
  • Hiroshi Aikata
    • 1
    Email author
  • Shintaro Takaki
    • 1
  • Yoshio Katamura
    • 1
  • Akira Hiramatsu
    • 1
  • Koji Waki
    • 1
  • Shoichi Takahashi
    • 1
  • Masashi Hieda
    • 2
  • Naoyuki Toyota
    • 2
  • Katsuhide Ito
    • 2
  • Kazuaki Chayama
    • 1
  1. 1.Department of Medicine and Molecular Science, Division of Frontier Medical Science, Programs for Applied Biomedicine, Graduate School of Biomedical ScienceHiroshima UniversityHiroshimaJapan
  2. 2.Department of Radiology, Division of Medical Intelligence and Informatics, Programs for Applied Biomedicine, Graduate School of Biomedical ScienceHiroshima UniversityHiroshimaJapan

Personalised recommendations